Asia Pacific Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024

List of Tables

The Asia Pacific Diabetic Neuropathy Treatment Market would witness market growth of 8.2% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $522.6 million by 2031. The Japan market is registering a CAGR of 7.5% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 8.8% during (2024 - 2031).

Another factor contributing to the growth of the diabetic neuropathy treatment market is the expanding range of treatment options available. Traditionally, the management of diabetic neuropathy has focused on controlling blood sugar levels and relieving symptoms such as pain and discomfort.

Moreover, these approaches remain important, there has been a shift towards a more comprehensive treatment strategy that addresses the underlying causes of nerve damage and aims to prevent or reverse the condition's progression.

India is experiencing a significant increase in diabetes prevalence, driven by factors such as urbanization, sedentary lifestyles, and dietary changes. Based on data from the National Library of Medicine, the estimated number of individuals with diabetes in India in 2019 was 77 million, and this figure is projected to surpass 134 million by 2045. It is projected that approximately 592 million individuals will perish from diabetes by 2035.

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

Abbott Laboratories
Eli Lilly And Company
Pfizer, Inc.
Lupin Limited
Astellas Pharma, Inc.
Glenmark Pharmaceuticals Limited
Boehringer Ingelheim International GmbH
Novartis AG
McKesson Corporation
GlaxoSmithKline PLC (GSK)

Asia Pacific Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Others

By Drug Class

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Country

China
Japan
India
South Korea
Australia
Malaysia
Rest of Asia Pacific

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1Asia Pacific Diabetic Neuropathy Treatment Market, by Distribution Channel
- 1.4.2Asia Pacific Diabetic Neuropathy Treatment Market, by Drug Class
- 1.4.3Asia Pacific Diabetic Neuropathy Treatment Market, by Disorder Type
- 1.4.4Asia Pacific Diabetic Neuropathy Treatment Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel

4.1Asia Pacific Hospitals Pharmacies Market by Country
4.2Asia Pacific Retail Pharmacies Market by Country
4.3Asia Pacific Others Market by Country

Chapter 5.Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class

5.1Asia Pacific Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2Asia Pacific Antidepressants Market by Country
5.3Asia Pacific Opioid Market by Country
5.4Asia Pacific Capsaicin Market by Country
5.5Asia Pacific Others Market by Country

Chapter 6.Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type

6.1Asia Pacific Peripheral Neuropathy Market by Country
6.2Asia Pacific Autonomic Neuropathy Market by Country
6.3Asia Pacific Proximal Neuropathy Market by Country
6.4Asia Pacific Focal Neuropathy Market by Country

Chapter 7.Asia Pacific Diabetic Neuropathy Treatment Market by Country

7.1China Diabetic Neuropathy Treatment Market
- 7.1.1China Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.2China Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.3China Diabetic Neuropathy Treatment Market by Disorder Type
7.2Japan Diabetic Neuropathy Treatment Market
- 7.2.1Japan Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.2Japan Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.3Japan Diabetic Neuropathy Treatment Market by Disorder Type
7.3India Diabetic Neuropathy Treatment Market
- 7.3.1India Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.2India Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.3India Diabetic Neuropathy Treatment Market by Disorder Type
7.4South Korea Diabetic Neuropathy Treatment Market
- 7.4.1South Korea Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.2South Korea Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.3South Korea Diabetic Neuropathy Treatment Market by Disorder Type
7.5Australia Diabetic Neuropathy Treatment Market
- 7.5.1Australia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.5.2Australia Diabetic Neuropathy Treatment Market by Drug Class
- 7.5.3Australia Diabetic Neuropathy Treatment Market by Disorder Type
7.6Malaysia Diabetic Neuropathy Treatment Market
- 7.6.1Malaysia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.6.2Malaysia Diabetic Neuropathy Treatment Market by Drug Class
- 7.6.3Malaysia Diabetic Neuropathy Treatment Market by Disorder Type
7.7Rest of Asia Pacific Diabetic Neuropathy Treatment Market
- 7.7.1Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.7.2Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
- 7.7.3Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8.Company Profiles

8.1Abbott Laboratories
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5Recent strategies and developments:
  - 8.1.5.1Acquisition and Mergers:
  - 8.1.5.2Trial and Approval:
- 8.1.6SWOT Analysis
8.2Eli Lilly And Company
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional Analysis
- 8.2.4Research & Development Expenses
- 8.2.5Recent strategies and developments:
  - 8.2.5.1Acquisition and Mergers:
- 8.2.6SWOT Analysis
8.3Pfizer, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Regional & Segmental Analysis
- 8.3.4Research & Development Expense
- 8.3.5SWOT Analysis
8.4Lupin Limited
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expense
- 8.4.5SWOT Analysis
8.5Astellas Pharma, Inc.
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5SWOT Analysis
8.6Glenmark Pharmaceuticals Limited
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Boehringer Ingelheim International GmbH
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional & Segmental Analysis
- 8.7.4Research & Development Expenses
- 8.7.5SWOT Analysis
8.8Novartis AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5Recent strategies and developments:
  - 8.8.5.1Acquisition and Mergers:
- 8.8.6SWOT Analysis
8.9McKesson Corporation
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental Analysis
- 8.9.4Research & Development Expense
- 8.9.5SWOT Analysis
8.10.GlaxoSmithKline PLC (GSK)
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expense
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1Asia Pacific Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2Asia Pacific Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5Asia Pacific Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6Asia Pacific Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7Asia Pacific Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8Asia Pacific Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9Asia Pacific Others Market by Country, 2020 - 2023, USD Million
TABLE 10Asia Pacific Others Market by Country, 2024 - 2031, USD Million
TABLE 11Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13Asia Pacific Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14Asia Pacific Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15Asia Pacific Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16Asia Pacific Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17Asia Pacific Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18Asia Pacific Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19Asia Pacific Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20Asia Pacific Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21Asia Pacific Others Market by Country, 2020 - 2023, USD Million
TABLE 22Asia Pacific Others Market by Country, 2024 - 2031, USD Million
TABLE 23Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25Asia Pacific Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26Asia Pacific Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27Asia Pacific Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28Asia Pacific Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29Asia Pacific Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30Asia Pacific Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31Asia Pacific Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32Asia Pacific Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33Asia Pacific Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34Asia Pacific Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35China Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36China Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37China Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38China Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39China Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40China Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41China Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42China Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43Japan Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44Japan Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45Japan Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46Japan Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47Japan Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48Japan Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49Japan Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50Japan Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51India Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52India Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53India Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54India Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55India Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56India Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57India Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58India Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59South Korea Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60South Korea Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61South Korea Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62South Korea Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63South Korea Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64South Korea Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65South Korea Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66South Korea Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67Australia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 68Australia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 69Australia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 70Australia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 71Australia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 72Australia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 73Australia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 74Australia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 75Malaysia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 76Malaysia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 77Malaysia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 78Malaysia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 79Malaysia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 80Malaysia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 81Malaysia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 82Malaysia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 83Rest of Asia Pacific Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 84Rest of Asia Pacific Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 85Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 86Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 87Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 88Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 89Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 90Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 91Key Information - Abbott Laboratories
TABLE 92Key Information - Eli Lilly And Company
TABLE 93Key Information - Pfizer, Inc.
TABLE 94Key Information - Lupin Limited
TABLE 95key information - Astellas Pharma, Inc.
TABLE 96Key Information - Glenmark Pharmaceuticals Limited
TABLE 97Key Information - Boehringer Ingelheim International GmbH
TABLE 98Key Information - Novartis AG
TABLE 99Key Information - McKesson Corporation
TABLE 100Key Information - GlaxoSmithKline PLC

Asia Pacific Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

Description

Table of Contents